Literature DB >> 8729728

Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.

P O Collinson1, C J Hjelm, R Canepo-Anson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8729728     DOI： 10.1177/000456329603300213

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN： 0004-5632            Impact factor:   2.057


× No keyword cloud information.
  4 in total

1.  Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.

Authors:  A O Olukoga
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

Review 2.  Paradoxical and bidirectional drug effects.

Authors:  Silas W Smith; Manfred Hauben; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2012-03-01       Impact factor: 5.606

Review 3.  Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future.

Authors:  Daniel H van Raalte; Min Li; P Haydn Pritchard; Kishor M Wasan
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

4.  Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.

Authors:  Michel Farnier; Qian Dong; Arvind Shah; Amy O Johnson-Levonas; Philippe Brudi
Journal:  Lipids Health Dis       Date:  2011-11-16       Impact factor: 3.876
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.